Colossal Biosciences
Bringing extinct species back to life
About Colossal Biosciences
Colossal Biosciences is using CRISPR gene editing to de-extinct the woolly mammoth, thylacine (Tasmanian tiger), and dodo. Beyond de-extinction, their breakthroughs in gene editing and cold-weather biology create platform technologies for conservation and medicine.
Colossal Biosciences website preview
Company facts
- Category
- AI
- Funding stage
- Series C
- Total raised
- $225M
- Founded
- 2021
- Team size
- 50-200
- HQ
- Dallas
- Country
- USA
- Website
- colossal.com
Founders of Colossal Biosciences
- Ben Novak
- George Church
Investors backing Colossal Biosciences
- BOLD Capital
- Winklevoss Capital
Frequently asked questions
What does Colossal Biosciences do?
Colossal Biosciences is using CRISPR gene editing to de-extinct the woolly mammoth, thylacine (Tasmanian tiger), and dodo. Beyond de-extinction, their breakthroughs in gene editing and cold-weather biology create platform technologies for conservation and medicine.
Where is Colossal Biosciences based?
Colossal Biosciences is based in Dallas, USA.
When was Colossal Biosciences founded?
Colossal Biosciences was founded in 2021.
How much has Colossal Biosciences raised?
Colossal Biosciences has raised $225M in their Series C round.
Who founded Colossal Biosciences?
Colossal Biosciences was founded by Ben Novak, George Church.
Who has invested in Colossal Biosciences?
Colossal Biosciences is backed by BOLD Capital, Winklevoss Capital.